The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Investigating bispecific antibodies in CLL
In this video, Parag Jasani, FRCPath, MBBS, MRCP, Royal Free London NHS Foundation Trust, London, UK, comments on the exploration of bispecific antibodies in chronic lymphocytic leukemia (CLL), mentioning epcoritamab and NVG-111. Dr Jasani explains that NVG-111, a bispecific antibody developed by his group, has been modified to incorporate autoregulation technology to prevent cytokine release syndrome (CRS). This approach has shown promising results in animal models, and plans are underway for an upcoming clinical trial. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are not that many antibodies. At ASH last year, there was some data presented on epcoritamab. 40 patients were studied in that study. A couple of years ago, I presented data on NVG-111, which is our ROR1 bispecific antibody. And again, I’ll present some updated data about this at the meeting tomorrow.
So what our group has done is they have modified our original NVG-111 antibody to add in an autoregulation technology within the same molecule, and what it does is prevent the toxicity due to cytokine release...
There are not that many antibodies. At ASH last year, there was some data presented on epcoritamab. 40 patients were studied in that study. A couple of years ago, I presented data on NVG-111, which is our ROR1 bispecific antibody. And again, I’ll present some updated data about this at the meeting tomorrow.
So what our group has done is they have modified our original NVG-111 antibody to add in an autoregulation technology within the same molecule, and what it does is prevent the toxicity due to cytokine release. And we have good animal model data and we are going to embark on clinical trials and the first patient hopefully will be dosed towards the end of this year so I’m looking forward to how it works.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
